Literature DB >> 8980155

L-arginine is unlikely to exert neuroendocrine effects in humans via the generation of nitric oxide.

M Korbonits1, P J Trainer, G Fanciulli, O Oliva, A Pala, A Dettori, M Besser, G Delitala, A B Grossman.   

Abstract

There is now considerable evidence that nitric oxide is an important neuroregulatory agent, but there has been very little investigation of its possible role in neuroendocrine mechanisms in humans. We have investigated the effects of two nitric oxide precursors, L-arginine and molsidomine, under basal conditions on the pituitary hormones growth hormone (GH), prolactin, luteinizing hormone, follicle-stimulating hormone, thyrotrophin, adrenocorticotrophin (ACTH) and vasopressin, and also on serum cortisol; we have also studied the effect of L-arginine on circulating prolactin, ACTH and cortisol in normal human subjects under hypoglycaemic stress. L-Arginine stimulated both GH and prolactin release under basal conditions but had no effect on the other hormones studied, while the nitric oxide donor molsidomine showed no effect on any hormone studied. L-Arginine potentiated the hypoglycaemia-stimulated release of ACTH but did not influence the rise in GH. The current studies suggest that the effects of L-arginine on the stimulation of GH and prolactin release are unlikely to be mediated via the generation of nitric oxide.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8980155     DOI: 10.1530/eje.0.1350543

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  2 in total

1.  Nitric oxide stimulates growth hormone secretion from human fetal pituitaries and cultured pituitary adenomas.

Authors:  Tami Rubinek; Hadara Rubinfeld; Moshe Hadani; Gad Barkai; Ilan Shimon
Journal:  Endocrine       Date:  2005-11       Impact factor: 3.633

Review 2.  Recent advances in neuropeptide-related omics and gene editing: Spotlight on NPY and somatostatin and their roles in growth and food intake of fish.

Authors:  Xiaozheng Yu; Haijun Yan; Wensheng Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-10-04       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.